Regulatory
Roche’s Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA’s Accelerated Approval
Shots: The accelerated approval is based on P-Ib/II GO29365 study results involves assessing of Polivy + bendamustine + Rituxan (BR)/Gazyva (obinutuzumab) vs BR in patients with r/r follicular lymphoma or […]readmore
